{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:11:58Z","timestamp":1789506718153,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI17\/337"],"award-info":[{"award-number":["PI17\/337"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128940","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T16:15:47Z","timestamp":1784736947000},"page":"128940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Persistent vaccine-type invasive pneumococcal disease in children despite high PCV13 coverage: the role of serotype 3"],"prefix":"10.1016","volume":"88","author":[{"given":"Pilar","family":"Ciruela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Broner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Moraga-Llop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariona F.","family":"de Sevilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conchita","family":"Izquierdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaresh","family":"P\u00e9rez-Arg\u00fcello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e0","family":"Gonz\u00e1lez-Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"D\u00edaz-Conradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Soldevila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Vi\u00f1ado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Alcaraz-Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorgina","family":"Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Esteva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Mu\u00f1oz-Almagro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2026.128940_bb0005","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1473-3099(24)00665-0","article-title":"Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis","volume":"25","author":"Bennett","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"48","key":"10.1016\/j.vaccine.2026.128940_bb0010","doi-asserted-by":"crossref","first-page":"9020","DOI":"10.1016\/j.vaccine.2011.09.034","article-title":"Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7-59 months. A matched case-control study","volume":"29","author":"Dom\u00ednguez","year":"2011","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128940_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183191","article-title":"Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7\u201359 months. A matched case-control study","volume":"12","author":"Dom\u00ednguez","year":"2017","journal-title":"PLoS One"},{"issue":"29","key":"10.1016\/j.vaccine.2026.128940_bb0020","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1016\/j.vaccine.2022.05.011","article-title":"Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study","volume":"40","author":"Savulescu","year":"2022","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128940_bb0025","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-0836","article-title":"Pneumococcal conjugate vaccine breakthrough infections: 2001-2016","volume":"145","author":"Adebanjo","year":"2020","journal-title":"Pediatrics"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128940_bb0030","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.vaccine.2011.12.048","article-title":"The concept of vaccination failure","volume":"30","author":"Heininger","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128940_bb0035","series-title":"2023 report Microbiological Notification System of Catalonia (SNMC) [internet]","article-title":"Epidemiology of invasive pneumococcal disease in Catalonia","author":"Ciruela","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128940_bb0040","series-title":"Laboratory methods for the diagnosis of meningitis caused by Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae: WHO manual","author":"Castillo","year":"2011"},{"key":"10.1016\/j.vaccine.2026.128940_bb0045","series-title":"Morbidity and Mortality Weekly Report General Recommendations on Immunization Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP) [Internet]","volume":"Vol. 51","author":"Centers for Disease Control and Prevention C","year":"2002"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128940_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11121750","article-title":"Pneumococcal vaccine breakthrough and failure in infants and children: a narrative review","volume":"11","author":"Feemster","year":"2023","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128940_bb0055","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/jcm.35.3.764-766.1997","article-title":"Dot blot assay for the serotyping of pneumococci","volume":"35","author":"Fenoll","year":"1997","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2026.128940_bb0060","doi-asserted-by":"crossref","unstructured":"Selva L, Berger C, Garcia-Garcia JJ, De Paz H, Nadal D, Mu\u00f1oz-Almagro C. Direct identification of Streptococcus pneumoniae capsular types in pleural fluids by using multiplex PCR combined with automated fluorescence-based capillary electrophoresis. J Clin Microbiol [Internet] Am Soc Microbiol; 2014 [cited 2021 Mar 2]. p. 2736\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24740085\/ doi:https:\/\/doi.org\/10.1128\/JCM.00906-14 PubMed PMID: 24740085.","DOI":"10.1128\/JCM.00906-14"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128940_bb0065","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.00741-23","article-title":"Comparison of next generation technologies and bioinformatics pipelines for capsular typing of Streptococcus pneumoniae","volume":"61","author":"Henares","year":"2023","journal-title":"J Clin Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128940_bb0070","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.01150-21","article-title":"Serotypes and clonal composition of Streptococcus pneumoniae isolates causing IPD in children and adults in Catalonia before 2013 to 2015 and after 2017 to 2019 systematic introduction of PCV13","volume":"9","author":"Redin","year":"2021","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.vaccine.2026.128940_bb0075","doi-asserted-by":"crossref","unstructured":"Abramson JS, Baker CJ, Fisher MC, Gerber MA, Meissner HC, Murray DL, et al. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics [Internet]. Pediatrics; 2000 [cited 2025 Dec 5]. p. 362\u20136. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/10920169\/ doi:https:\/\/doi.org\/10.1542\/peds.106.2.362 PubMed PMID: 10920169.","DOI":"10.1542\/peds.106.2.362"},{"issue":"50","key":"10.1016\/j.vaccine.2026.128940_bb0080","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1016\/j.vaccine.2016.10.050","article-title":"Pneumococcal conjugate vaccine failure in children: a systematic review of the literature","volume":"34","author":"Oligbu","year":"2016","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128940_bb0085","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/14760584.2022.2012455","article-title":"A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children","volume":"21","author":"Mungall","year":"2022","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128940_bb0090","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3201\/eid2606.190951","article-title":"Failures of 13-valent conjugated pneumococcal vaccine in age-appropriately vaccinated children 2\u201359 months of age, Spain","volume":"26","author":"Hern\u00e1ndez","year":"2020","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128940_bb0095","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1473-3099(23)00706-5","article-title":"Invasive pneumococcal disease 3 years after introduction of a reduced 1+1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study","volume":"24","author":"Bertran","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128940_bb0100","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(14)70822-9","article-title":"Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study","volume":"14","author":"Andrews","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128940_bb0105","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/INF.0000000000004192","article-title":"Serotype 3 antibody response and antibody functionality compared to serotype 19A following 13-valent pneumococcal conjugate immunization in children","volume":"43","author":"Fuji","year":"2024","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128940_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiph.2025.103034","article-title":"Post-pandemic increase in pediatric invasive pneumococcal disease driven by serotype 3","volume":"19","author":"Benito Arribas","year":"2026","journal-title":"J Infect Public Health"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128940_bb0115","article-title":"Streptococcus pneumoniae serotype 3 population structure in the era of conjugate vaccines, 2001-2018","volume":"10","author":"Cella","year":"2024","journal-title":"Microb Genom"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128940_bb0120","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1440-1843.2011.02035.x","article-title":"Pleural fluid nucleic acid testing enhances pneumococcal surveillance in children","volume":"17","author":"Strachan","year":"2012","journal-title":"Respirology"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128940_bb0125","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.vaccine.2019.12.060","article-title":"Who is at risk of 13-valent conjugated pneumococcal vaccine failure?","volume":"38","author":"Yildirim","year":"2020","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128940_bb0130","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s10096-011-1468-7","article-title":"Serotype 3 is a common serotype causing invasive pneumococcal disease in children less than 5 years old, as identified by real-time PCR","volume":"31","author":"Selva","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128940_bb0135","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/eurpub\/ckw089","article-title":"Pneumococcal pneumonia vaccine breakthroughs and failures after 13-valent pneumococcal conjugated vaccine","volume":"26","author":"Almeida","year":"2016","journal-title":"Eur J Public Health"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128940_bb0140","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/INF.0000000000000041","article-title":"Parapneumonic pleural effusions caused by Streptococcus pneumoniae serotype 3 in children immunized with 13-valent conjugated pneumococcal vaccine","volume":"33","author":"Antachopoulos","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128940_bb0145","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/cid\/ciz221","article-title":"Changes in invasive pneumococcal disease spectrum after 13-valent pneumococcal conjugate vaccine implementation","volume":"70","author":"Levy","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128940_bb0150","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1080\/14760584.2023.2292773","article-title":"Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children","volume":"23","author":"Ryman","year":"2024","journal-title":"Expert Rev Vaccines"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128940_bb0155","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.3201\/eid2811.211741","article-title":"Effect of COVID-19 pandemic on invasive pneumococcal disease in children, Catalonia, Spain","volume":"28","author":"Ciruela","year":"2022","journal-title":"Emerg Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:45:08Z","timestamp":1789505108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26007498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"alternative-id":["S0264410X26007498"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128940","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistent vaccine-type invasive pneumococcal disease in children despite high PCV13 coverage: the role of serotype 3","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128940","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128940"}}